Opinion|Videos|April 4, 2025
Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
Panelists discuss how medical professionals select PSMA PET tracers based on factors such as diagnostic accuracy, tracer availability, patient-specific considerations, and logistical aspects such as half-life and production facilities. Fluorine-18 (^18F)–labeled tracers, such as ^18F-PSMA-1007, offer logistical advantages due to their longer half-life and higher image resolution, facilitating broader clinical application.
Advertisement
Video content above is prompted by the following:
- What factors do you consider when selecting a PSMA PET tracer for a particular patient or clinical scenario?
- When might you opt for F18 vs Ga58, and how do available data inform your decision?
- Meta-analysis F18 vs G68 (Huang et al. Prostate Cancer. 2023)
- Do you still see a role for Axumin? If so, in what scenarios?
Advertisement
Related to this article
Phase 3 TALAPRO-3 data support the FDA approval of talazoparib/enzalutamide in HRR gene-altered metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.
Long-term PEACE-1 data showed that adding abiraterone acetate plus prednisone to standard of care extended median OS by 1.5 years in de novo metastatic CSPC.
Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.
Posters covered a companion diagnostic for niraparib plus AAP, response biomarkers for radioligand therapy, and genomic profile differences in metastatic CRPC.
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Improves Survival vs Chemotherapy in Pretreated Endometrial Cancer
2
Pembrolizumab Improves PFS Over Chemo in dMMR Endometrial Cancer
3
Cemiplimab Shows Real-World Efficacy in Advanced NSCLC Study
4
ctDNA Clearance Tracks With Survival on Pembrolizumab in HPV-Negative HNSCC
5